SCHEMBL16480792

SCHEMBL16480792

CC(C)OC(=O)C(C)NP1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)[C@](C)(Cl)[C@@H]2O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 2/20 0.35
▸ PDE3A Q14432 3/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ SLC29A1 Q99808 1/20 0.35
▸ LMNA P02545 3/20 0.32
▸ CACNA1F O60840 2/20 0.32
▸ ALB P02768 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ CACNA1D Q01668 2/20 0.32
▸ CACNA1S Q13698 2/20 0.32
▸ CACNA1C Q13936 2/20 0.32
▸ POLG P54098 2/20 0.32
▸ THRB P10828 1/20 0.31
▸ MTOR P42345 1/20 0.31
▸ MDM2 Q00987 1/20 0.31
▸ NCOA1 Q15788 1/20 0.31
▸ NCOA3 Q9Y6Q9 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15588666 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL16480765 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL16480787 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL15588664 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL16480770 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL15588667 1.00 POLA1 (0.35) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL20221801 0.90 PDE3A (0.43) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL20221826 0.90 PDE3A (0.43) POLA1PDE3APDE4DSLC29A1LMNA
SCHEMBL16480749 0.84 CYP3A4 (0.44) POLA1CYP3A4CYP2C9
SCHEMBL15588864 0.84 CYP3A4 (0.44) POLA1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906579-B1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC (US) 2018-04-18 — — EP disclosed
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC 2016-03-24 — — US disclosed
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC 2016-03-24 — — US disclosed
WO-2014058801-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS, INC. (US) 2014-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION SLC28A2, SLC28A1, SLC29A2 POLA1 287/4885PDE3A 1190/4885PDE4D 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback